Cargando…
Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients
We recently reported the SART3 tumour-rejection antigen as possessing tumour epitopes capable of inducing HLA-class I-restricted cytotoxic T lymphocytes (CTLs). This study investigated expression of the SART3 antigen in breast cancer to explore an appropriate molecule for use in specific immunothera...
Autores principales: | Suefuji, Y, Sasatomi, T, Shichijo, S, Nakagawa, S, Deguchi, H, Koga, T, Kameyama, T, Itoh, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363830/ https://www.ncbi.nlm.nih.gov/pubmed/11286471 http://dx.doi.org/10.1054/bjoc.2000.1690 |
Ejemplares similares
-
Expression of the SART‐1 Antigens in Uterine Cancers
por: Matsumoto, Hajime, et al.
Publicado: (1998) -
Expression of SART3 Tumor‐rejection Antigen in Gastric Cancers
por: Niiya, Fumihiko, et al.
Publicado: (2000) -
Mouse Homologue of the Human SART3 Gene Encoding Tumor‐rejection Antigen
por: Harada, Kenji, et al.
Publicado: (2000) -
Sequence Analysis of Genes Encoding Rodent Homologues of the Human Tumor‐rejection Antigen SART‐1
por: Gotoh, Masashi, et al.
Publicado: (1998) -
Cytokines Required for Induction of Histocompatibility Leukocyte Antigen‐class I‐restricted and Tumor‐specific Cytotoxic T Lymphocytes by a SART1‐derived Peptide
por: Matsunaga, Kazuko, et al.
Publicado: (1999)